Wedbush analyst Liana Moussatos reiterated a Hold rating on Omeros Corp (NASDAQ: OMER) today and set a price target of $20. The company’s shares opened today at $22.28.
According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 1.1% and a 42.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omeros Corp with a $29 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.20 and a one-year low of $8.36. Currently, Omeros Corp has an average volume of 787K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.
